Quarterly report pursuant to Section 13 or 15(d)

Loans Receivable (Tables)

v3.24.3
Loans Receivable (Tables)
9 Months Ended
Sep. 30, 2024
Loans Receivable  
Schedules of loans receivable

A breakdown of the loans receivable terms and balances are as follows:

Loans receivable

    

September 30, 2024

    

December 31, 2023

Teneo Fund SPVi LLC Note

$

5,501

$

5,622

Pharma EU, LLC Note

1,410

A&R Note

710

SSZ and Elev8 Note

1,002

Pure Hana Synergy Note

224

Little Beach Harvest Note

Total loans receivable

$

5,501

$

8,968

Less allowance for expected credit losses

(4,556)

(7,902)

Loans receivable

$

945

$

1,066

Schedule of analysis of credit quality of loans receivable

The following tables present an analysis of the credit quality of loans receivable, together with impairment losses recognized based on lifetime CECL reserves:

As of September 30, 2024

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

5,501

$

(4,556)

$

945

Third party guarantee

No collateral

Net loans receivable

$

5,501

$

(4,556)

$

945

As of December 31, 2023

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

7,334

$

(6,268)

$

1,066

Third party guarantee

1,410

(1,410)

No collateral

224

(224)

Net loans receivable

$

8,968

$

(7,902)

$

1,066